Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy

J. M. Denefrio; D. W. East; M. B. Troner; C. L. Vogel

Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy

J. M. Denefrio, D. W. East, M. B. Troner, C. L. Vogel

Medicine

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

The combination of mitomycin C and vinblastine in the dose and schedule used in this study (6 and 5 mg/m², respectively, every 14 days) was of little clinical efficacy in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches.

Original language	English (US)
Pages (from-to)	2113-2115
Number of pages	3
Journal	Cancer Treatment Reports
Volume	62
Issue number	12
State	Published - Dec 1 1978

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{dd26e8cd7d0548acb18d9595d823fa7c,

title = "Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy",

abstract = "The combination of mitomycin C and vinblastine in the dose and schedule used in this study (6 and 5 mg/m2, respectively, every 14 days) was of little clinical efficacy in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches.",

author = "Denefrio, {J. M.} and East, {D. W.} and Troner, {M. B.} and Vogel, {C. L.}",

year = "1978",

month = dec,

day = "1",

language = "English (US)",

volume = "62",

pages = "2113--2115",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy

AU - Denefrio, J. M.

AU - East, D. W.

AU - Troner, M. B.

AU - Vogel, C. L.

PY - 1978/12/1

Y1 - 1978/12/1

N2 - The combination of mitomycin C and vinblastine in the dose and schedule used in this study (6 and 5 mg/m2, respectively, every 14 days) was of little clinical efficacy in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches.

AB - The combination of mitomycin C and vinblastine in the dose and schedule used in this study (6 and 5 mg/m2, respectively, every 14 days) was of little clinical efficacy in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches.

UR - http://www.scopus.com/inward/record.url?scp=0018236249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018236249&partnerID=8YFLogxK

M3 - Article

C2 - 751719

AN - SCOPUS:0018236249

VL - 62

SP - 2113

EP - 2115

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

ER -

Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this